A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

Grant

Date/time Interval

  • March 30, 2018 - March 29, 2021
  • Total Award Amount

  • 86420.00
  • Direct Costs

  • 66477.00
  • Sponsor Award Id

  • Contributor

  • Maria Acosta Lara   Investigator  
  • Maria Danila MD, MSc, MSPH   Investigator  
  • Steven Duncan   Principal Investigator  
  • Swati Gulati   Investigator  
  • Tejaswini Kulkarni   Investigator  
  • Tracy Luckhardt   Investigator